Glaucoma is a serious irreversible blinding disease. The pathogenesis is still unknown, and the diagnosis and treatment effect is not good. An effective early diagnosis method is urgently needed. In recent years, a number of glaucoma-related biomarkers have been discovered. In order to promote clinical application of these biomarkers, a series of studies are actively carried out to clarify specificity and sensitivity of these molecules, to verify the criteria by clinical randomized controlled trials, and to provide large sample data by multi-center clinical trials. However, the samples of these biomarkers are provided by patients who have been diagnosed with glaucoma by clinical examinations. The differences may represent the molecular features of middle-stage and advanced glaucoma. Whether they are helpful for early diagnosis and the exploration of pathological mechanisms should be further investigated. This article describes the potential molecular targets that can help in diagnosis of glaucoma from the aspects of DNA, RNA and protein, and discusses further research pathways and clinical application prospects. It is hoped to explore the effective molecular marker for early diagnosis of glaucoma. (Chin J Ophthalmol, 2021, 57: 707-711)

Glaucoma; Early diagnosis; Biomarkers; Molecular diagnostic techniques